Sign in
ALVR Stock Price, Chart, Stats & News
AlloVir, Inc.
Save
49.48M
Market cap
–
Current P/E
–
Forward P/E
ALVR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -35.68% |
ROE | -73.11% |
D/E | 0.02x |
Interest coverage ratio | 31.98x |
ALVR valuation
P/E | – |
P/S | – |
P/B | 19.00x |
P/CF | -39.03x |
P/FCF | -1.28x |
P/OCF | -39.03x |
PEG | -0.82x |
EV multiple | -3.17x |
About
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Similar securities
Based on sector and market capitalization
Report issue